Nanobiotechnology and blood substitutes
2011
Nanobiotechnology and Blood Substitutes
publication
Evidence: moderate
Author Information
Author(s): Rajiv Saini, Sugandha Sharma
Primary Institution: Rural Dental College-Loni, Maharashtra, India
Hypothesis
Can nanobiotechnology improve the development of blood substitutes?
Conclusion
Nanobiotechnology has the potential to create effective blood substitutes that can be used in clinical settings.
Supporting Evidence
- Nanobiotechnology can create artificial red blood cells that can be used in emergencies.
- First-generation engineered hemoglobin is already in clinical trials.
- New generations of modified hemoglobin are being developed to improve safety and efficacy.
Takeaway
Scientists are trying to make artificial blood using tiny particles so that we can have blood ready for emergencies without waiting.
Methodology
The study discusses various approaches to developing artificial red blood cells using nanobiotechnology.
Limitations
It takes many years to develop blood substitutes, and there is a lack of basic information that has led to failures.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website